Over the last half-decade, we have witnessed game-changing developments within the cannabinoid field, driving it into a new era of rigorous research, promising clinical trials and multimillion-dollar deals.
The 5th International Cannabinoid-Derived Pharmaceuticals Summit brings together drug developers working on the complex production of both plant-based, biosynthetic and synthetic endocannabinoid system modulators. An elite faculty of speakers will present on crucial topics such as rigorous clinical trial data exchange, and guide discussion through vital non-clinical focus points such as IP and funding strategy – as well as cutting edge insights from the academic world. Meet face-to-face with decision-makers from the likes of Jazz Pharmaceuticals Greenwich Biosciences, ACHEM, Cannvalate, Cannabics Pharmaceuticals, Oxford Cannabinoid Technologies and many more at the first physical cannabinoid conference of the year.
What’s new for 2022?
- The lack of human evidence for the mechanism of action for cannabinoids major and minor in different therapeutic areas – led by Anthony Almada from Imaginutrition and other key stakeholders
- The wealth of RWE that can be utilised in a way that could uncover further potential for cannabinoid therapeutics with Jeff Chen, Radicle
- For the first time ever, an MP from UK government will discuss the ins and outs of drug reform in the UK and the current roadblocks
Click here to find out more
The post 5th International Cannabinoid-Derived Pharmaceuticals Summit appeared first on .
